The Chemours Company Reports Second Quarter 2023 Results and Announces Closure of Titanium Dioxide Plant in Taiwan
- Net Sales of $1.6 billion
- Adjusted EBITDA of $324 million
- Comprehensive settlement of PFAS-related drinking water claims totaling $592 million
- Sale of Glycolic Acid business for $137 million
- Launch of THE Mobility F.C. Membranes Company
- Closure of Kuan Yin titanium dioxide manufacturing facility
- Lowered full-year adjusted EBITDA guidance by 9% at the midpoint
- Net loss of $(376) million with EPS of $(2.52)
- Adjusted net income of $167 million with adjusted EPS of $1.10
- Lower net sales in Titanium Technologies and Advanced Performance Materials
- Decreased adjusted EBITDA by 32% in Q2 2023
- Weaker second half demand visibility
Solid second quarter despite signs of demand weakness, FY 2023 Adjusted EBITDA guidance lowered
Second Quarter 2023 Results & Highlights
-
Net Sales of
$1.6 billion -
Net Loss of
$(376) million $(2.52) -
Adjusted Net Income2 of
$167 million $1.10 -
Adjusted EBITDA2 of
$324 million $3 million -
Announced shutdown of TT’s Kuan Yin,
Taiwan manufacturing facility as part of overall cost optimization efforts -
Reached comprehensive settlement of PFAS-related drinking water claims of a defined class of
U.S. public water systems; Chemours’ share totaling$592 million -
Agreed to sell Chemours’ Glycolic Acid business to PureTech Scientific Inc. for
$137 million - Launched operations at THE Mobility F.C. Membranes Company as a part of Chemours’ joint venture
- Issued Chemours’ sixth Sustainability Report highlighting significant progress towards 2030 CRC goals
-
On July 26, 2023, the Company's Board of Directors approved a third quarter dividend of
$0.25 -
Given weaker 2H demand visibility, we now anticipate full year Adjusted EBITDA to be between
$1.10 0 billion$1.17 5 billion$325 million
“Our second quarter performance underscores the strength of our industry-leading businesses despite increasing economic uncertainty. In Thermal & Specialized Solutions, we delivered record Net Sales and Adjusted EBITDA, and in Advanced Performance Materials demonstrated the strength of our Performance Solutions portfolio achieving double-digit growth,” said Mark Newman, Chemours President and CEO. “As part of our plan to improve the earnings power of our Titanium Technologies segment, we have decided to close our Kuan Yin facility. This action will enable us to optimize our manufacturing circuit without compromising our ability to meet customer demand and deliver significant recurring cost savings starting in the second half of 2023.”
Second quarter 2023 Net Sales of
Second quarter Net Loss was
_________________________
|
2 Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, referred to throughout, principally exclude the impact of recent legal settlements for legacy environmental matters and associated fees in addition to other items of a non-recurring nature – please refer to the attached "Reconciliation of GAAP Financial Measures to non-GAAP Financial Measures (Unaudited)”. |
3 Assumes future cash payments of approximately |
4 Includes |
Announcement of Closure of Taiwan Titanium Technologies Plant
The Company today announced the decision to close its Kuan Yin manufacturing facility. The decision comes as part of a comprehensive strategy to improve the earnings quality of TT – producers of the popular Ti-Pure™ brand – by optimizing its manufacturing circuit.
“Plant closures are incredibly difficult because of the impact on talented and hard-working people like our Kuan Yin colleagues who have been valued members of our company, as well as their families and the community. We are working closely with local leaders to help with this transition,” said Denise Dignam, President of Chemours Titanium Technologies. “Moving forward, Chemours remains committed to delivering excellent service to our customers and continuing to lead the industry in innovation and sustainability.”
The Kuan Yin site will stop producing dry titanium dioxide pigment on August 1, 2023, and decommissioning will begin immediately. Chemours sales and technical service teams will work closely with affected customers to maintain uninterrupted supply. The Company expects there will be no impact on product or service quality and no supply interruption during this transition.
Segment Results
Titanium Technologies
Delivering high-quality Ti-Pure™ pigment through customer-centered innovation and sustainability leadership
Q2 2023 |
Q2 2022 |
Change |
|
Titanium Technologies |
|
|
|
Net sales ($ millions) |
|
|
(27)% |
Adjusted EBITDA ($ millions) |
|
|
(60)% |
Adjusted EBITDA Margin |
|
|
(10) ppts |
In the second quarter, TT reported Net Sales of
On a sequential basis, Net Sales increased by
We anticipate the closure of our Kuan Yin facility to provide an annual run-rate cost savings of approximately
Our overall outlook anticipates a delayed recovery, with second half demand expected to be flat to slightly improved compared to the first half, given uneven and uncertain macroeconomic conditions globally.
Thermal & Specialized Solutions
Driving innovation in low GWP thermal management solutions to support customer transitions to more sustainable products
Q2 2023 |
Q2 2022 |
Change |
|
Thermal & Specialized Solutions |
|
|
|
Net sales ($ millions) |
|
|
|
Adjusted EBITDA ($ millions) |
|
|
|
Adjusted EBITDA Margin |
|
|
(0) ppts |
In the second quarter, TSS reported record Net Sales of
On a sequential basis, Net Sales increased by
Our outlook anticipates continued OpteonTM adoption in mobile and stationary applications ahead of the next EU and
Advanced Performance Materials
Creating a clean energy and advanced electronics powerhouse
Q2 2023 |
Q2 2022 |
Change |
|
Advanced Performance Materials |
|
|
|
Net sales ($ millions) |
|
|
(3)% |
Adjusted EBITDA ($ millions) |
|
|
(24)% |
Adjusted EBITDA Margin |
|
|
(6) ppt |
In the second quarter, APM reported Net Sales of
On a sequential basis, Net Sales were relatively flat. Price decreased by (1)%, and volume increased
Our outlook anticipates weaker second half demand for products in the Advanced Materials portfolio which serves economically sensitive end-markets, paired with continued elevated input costs, partially offset by improved customer demand for high-value, differentiated products in the Performance Solutions portfolio.
Other Segment
The Performance Chemicals and Intermediates business in Other Segment had Net Sales and Adjusted EBITDA in the second quarter 2023 of
Corporate and Other Activities
Corporate and Other was an offset to second quarter Adjusted EBITDA of
Liquidity
As of June 30, 2023, consolidated gross debt was
Cash provided by operating activities for the second quarter of 2023 was
Guidance
The Company is updating its full year 2023 Adjusted EBITDA guidance. The Company now expects full year 2023 Adjusted EBITDA to be within the range of
Mr. Newman concluded, "We take pride in the results achieved this quarter in a challenging macroeconomic environment and I would like to thank the entire Chemours team for remaining focused on delivering this strong performance. However, given the low visibility in certain order books and increasing uncertainties in the second half of the year, we are lowering our guidance accordingly. In light of our revised guidance, we are actively working to optimize our cost structure and enhance the earnings quality of the TT segment, as demonstrated by our actions at Kuan Yin. We remain focused on executing against our five strategic priorities and unlocking greater shareholder value over time.”
Conference Call
As previously announced, Chemours will hold a conference call and webcast exclusively for Q&A on July 28, 2023, at 8:00 AM Eastern Daylight Time. A transcript of the prepared remarks and additional presentation materials can be accessed by visiting the Events & Presentations page of Chemours' investor website, investors.chemours.com. A webcast replay of the conference call will be available on Chemours’ investor website.
_________________________
|
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials providing its customers with solutions in a wide range of industries with market-defining products, application expertise and chemistry-based innovations. We deliver customized solutions with a wide range of industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, general industrial, and oil and gas. Our flagship products include prominent brands such as Ti-Pure™, Opteon™, Freon™, Teflon™, Viton™, Nafion™, and Krytox™. The Company has approximately 6,600 employees and 29 manufacturing sites serving approximately 2,900 customers in approximately 120 countries. Chemours is headquartered in
For more information, we invite you to visit chemours.com or follow us on Twitter @Chemours or LinkedIn.
Non-GAAP Financial Measures
We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this press release, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Adjusted Effective Tax Rate, Return on Invested Capital and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making.
Management uses Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Adjusted Effective Tax Rate, Return on Invested Capital and Net Leverage Ratio to evaluate the Company's performance excluding the impact of certain noncash charges and other special items which we expect to be infrequent in occurrence in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.
Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, changes in environmental regulations in the
The Chemours Company
Consolidated Statements of Operations (Unaudited)
(Dollars in millions, except per share amounts)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
||||
Net sales |
|
$ |
1,643 |
|
|
$ |
1,915 |
|
|
$ |
3,179 |
|
|
$ |
3,679 |
|
Cost of goods sold |
|
|
1,233 |
|
|
|
1,418 |
|
|
|
2,401 |
|
|
|
2,697 |
|
Gross profit |
|
|
410 |
|
|
|
497 |
|
|
|
778 |
|
|
|
982 |
|
Selling, general, and administrative expense |
|
|
779 |
|
|
|
254 |
|
|
|
903 |
|
|
|
395 |
|
Research and development expense |
|
|
28 |
|
|
|
25 |
|
|
|
54 |
|
|
|
55 |
|
Restructuring, asset-related, and other charges |
|
|
(1 |
) |
|
|
1 |
|
|
|
15 |
|
|
|
12 |
|
Total other operating expenses |
|
|
806 |
|
|
|
280 |
|
|
|
972 |
|
|
|
462 |
|
Equity in earnings of affiliates |
|
|
13 |
|
|
|
16 |
|
|
|
25 |
|
|
|
28 |
|
Interest expense, net |
|
|
(48 |
) |
|
|
(40 |
) |
|
|
(90 |
) |
|
|
(82 |
) |
Other (expense) income, net |
|
|
(2 |
) |
|
|
38 |
|
|
|
(1 |
) |
|
|
44 |
|
(Loss) income before income taxes |
|
|
(433 |
) |
|
|
231 |
|
|
|
(260 |
) |
|
|
510 |
|
(Benefit from) provision for income taxes |
|
|
(57 |
) |
|
|
30 |
|
|
|
(30 |
) |
|
|
76 |
|
Net (loss) income |
|
|
(376 |
) |
|
|
201 |
|
|
|
(230 |
) |
|
|
434 |
|
Less: Net income attributable to non-controlling interests |
|
|
— |
|
|
|
— |
|
|
|
1 |
|
|
|
— |
|
Net (loss) income attributable to Chemours |
|
$ |
(376 |
) |
|
$ |
201 |
|
|
$ |
(231 |
) |
|
$ |
434 |
|
Per share data |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic (loss) earnings per share of common stock |
|
$ |
(2.52 |
) |
|
$ |
1.29 |
|
|
$ |
(1.55 |
) |
|
$ |
2.75 |
|
Diluted (loss) earnings per share of common stock |
|
|
(2.52 |
) |
|
|
1.26 |
|
|
|
(1.55 |
) |
|
|
2.69 |
|
The Chemours Company
Consolidated Balance Sheets (Unaudited)
(Dollars in millions, except per share amounts)
|
|
June 30, 2023 |
|
|
December 31, 2022 |
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
738 |
|
|
$ |
1,102 |
|
Restricted cash and restricted cash equivalents |
|
|
207 |
|
|
|
— |
|
Accounts and notes receivable, net |
|
|
890 |
|
|
|
626 |
|
Inventories |
|
|
1,446 |
|
|
|
1,404 |
|
Prepaid expenses and other |
|
|
64 |
|
|
|
82 |
|
Assets held for sale |
|
|
29 |
|
|
|
— |
|
Total current assets |
|
|
3,374 |
|
|
|
3,214 |
|
Property, plant, and equipment |
|
|
9,548 |
|
|
|
9,387 |
|
Less: Accumulated depreciation |
|
|
(6,358 |
) |
|
|
(6,216 |
) |
Property, plant, and equipment, net |
|
|
3,190 |
|
|
|
3,171 |
|
Operating lease right-of-use assets |
|
|
244 |
|
|
|
240 |
|
Goodwill |
|
|
102 |
|
|
|
102 |
|
Other intangible assets, net |
|
|
8 |
|
|
|
13 |
|
Investments in affiliates |
|
|
189 |
|
|
|
175 |
|
Restricted cash and restricted cash equivalents |
|
|
— |
|
|
|
202 |
|
Other assets |
|
|
553 |
|
|
|
523 |
|
Total assets |
|
$ |
7,660 |
|
|
$ |
7,640 |
|
Liabilities |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
1,009 |
|
|
$ |
1,251 |
|
Compensation and other employee-related cost |
|
|
78 |
|
|
|
121 |
|
Short-term and current maturities of long-term debt |
|
|
25 |
|
|
|
25 |
|
Current environmental remediation |
|
|
148 |
|
|
|
194 |
|
Other accrued liabilities |
|
|
930 |
|
|
|
300 |
|
Total current liabilities |
|
|
2,190 |
|
|
|
1,891 |
|
Long-term debt, net |
|
|
3,604 |
|
|
|
3,590 |
|
Operating lease liabilities |
|
|
196 |
|
|
|
198 |
|
Long-term environmental remediation |
|
|
473 |
|
|
|
474 |
|
Deferred income taxes |
|
|
58 |
|
|
|
61 |
|
Other liabilities |
|
|
329 |
|
|
|
319 |
|
Total liabilities |
|
|
6,850 |
|
|
|
6,533 |
|
Commitments and contingent liabilities |
|
|
|
|
|
|
||
Equity |
|
|
|
|
|
|
||
Common stock (par value |
|
|
2 |
|
|
|
2 |
|
Treasury stock, at cost (48,529,521 shares at June 30, 2023; 46,871,780 shares at December 31, 2022) |
|
|
(1,790 |
) |
|
|
(1,738 |
) |
Additional paid-in capital |
|
|
1,014 |
|
|
|
1,016 |
|
Retained earnings |
|
|
1,864 |
|
|
|
2,170 |
|
Accumulated other comprehensive loss |
|
|
(282 |
) |
|
|
(343 |
) |
Total Chemours stockholders’ equity |
|
|
808 |
|
|
|
1,107 |
|
Non-controlling interests |
|
|
2 |
|
|
|
— |
|
Total equity |
|
|
810 |
|
|
|
1,107 |
|
Total liabilities and equity |
|
$ |
7,660 |
|
|
$ |
7,640 |
|
The Chemours Company
Consolidated Statements of Cash Flows (Unaudited)
(Dollars in millions)
|
|
Six Months Ended June 30, |
|
|||||
|
|
2023 |
|
|
2022 |
|
||
Cash flows from operating activities |
|
|
|
|
|
|
||
Net (loss) income |
|
$ |
(231 |
) |
|
$ |
434 |
|
Adjustments to reconcile net income to cash provided by operating activities: |
|
|
|
|
|
|
||
Depreciation and amortization |
|
|
157 |
|
|
|
146 |
|
Gain on sales of assets and businesses, net |
|
|
— |
|
|
|
(27 |
) |
Equity in earnings of affiliates, net |
|
|
(21 |
) |
|
|
(23 |
) |
Amortization of debt issuance costs and issue discounts |
|
|
4 |
|
|
|
4 |
|
Deferred tax benefit |
|
|
(71 |
) |
|
|
(9 |
) |
Asset-related charges |
|
|
11 |
|
|
|
5 |
|
Stock-based compensation expense |
|
|
7 |
|
|
|
17 |
|
Net periodic pension cost |
|
|
4 |
|
|
|
4 |
|
Defined benefit plan contributions |
|
|
(7 |
) |
|
|
(7 |
) |
Other operating charges and credits, net |
|
|
(5 |
) |
|
|
(8 |
) |
Decrease (increase) in operating assets: |
|
|
|
|
|
|
||
Accounts and notes receivable |
|
|
(261 |
) |
|
|
(339 |
) |
Inventories and other operating assets |
|
|
26 |
|
|
|
(86 |
) |
(Decrease) increase in operating liabilities: |
|
|
|
|
|
|
||
Accounts payable and other operating liabilities |
|
|
329 |
|
|
|
182 |
|
Cash (used for) provided by operating activities |
|
|
(58 |
) |
|
|
293 |
|
Cash flows from investing activities |
|
|
|
|
|
|
||
Purchases of property, plant, and equipment |
|
|
(149 |
) |
|
|
(168 |
) |
Proceeds from sales of assets and businesses |
|
|
— |
|
|
|
33 |
|
Foreign exchange contract settlements, net |
|
|
(8 |
) |
|
|
(1 |
) |
Other investing activities |
|
— |
|
|
|
(9 |
) |
|
Cash used for investing activities |
|
|
(157 |
) |
|
|
(145 |
) |
Cash flows from financing activities |
|
|
|
|
|
|
||
Debt repayments |
|
|
(6 |
) |
|
|
(7 |
) |
Payments on finance leases |
|
|
(6 |
) |
|
|
(6 |
) |
Payments of debt issuance cost |
|
|
— |
|
|
|
(1 |
) |
Purchases of treasury stock, at cost |
|
|
(51 |
) |
|
|
(272 |
) |
Proceeds from exercised stock options, net |
|
|
9 |
|
|
|
48 |
|
Payments related to tax withholdings on vested stock awards |
|
|
(18 |
) |
|
|
(4 |
) |
Payments of dividends to the Company's common shareholders |
|
|
(75 |
) |
|
|
(78 |
) |
Cash received from non-controlling interest shareholder |
|
|
1 |
|
|
|
— |
|
Cash used for financing activities |
|
|
(146 |
) |
|
|
(320 |
) |
Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents |
|
|
2 |
|
|
|
(31 |
) |
Decrease in cash, cash equivalents, restricted cash and restricted cash equivalents |
|
|
(359 |
) |
|
|
(203 |
) |
Cash, cash equivalents, restricted cash and restricted cash equivalents at January 1, |
|
|
1,304 |
|
|
|
1,551 |
|
Cash, cash equivalents, restricted cash and restricted cash equivalents at June 30, |
|
$ |
945 |
|
|
$ |
1,348 |
|
|
|
|
|
|
|
|
||
Supplemental cash flows information |
|
|
|
|
|
|
||
Non-cash investing and financing activities: |
|
|
|
|
|
|
||
Purchases of property, plant, and equipment included in accounts payable |
|
$ |
53 |
|
|
$ |
41 |
|
Treasury Stock repurchased, not settled |
|
1 |
2 |
|
||||
The Chemours Company
Segment Financial and Operating Data (Unaudited)
(Dollars in millions)
Segment Net Sales |
|
|
|
|
|
|
|
|
|
|
|
|
Three Months |
|
|
|
|
|
||||||
|
|
|
|
|
|
|
Ended |
|
|
Sequential |
|
|||||||||||||
|
Three Months Ended June 30, |
|
|
Increase / |
|
|
March 31, |
|
|
Increase / |
|
|||||||||||||
|
2023 |
|
|
2022 |
|
|
(Decrease) |
|
|
2023 |
|
|
(Decrease) |
|
||||||||||
Titanium Technologies |
$ |
|
707 |
|
|
$ |
|
968 |
|
|
$ |
|
(261 |
) |
|
$ |
|
632 |
|
|
$ |
|
75 |
|
Thermal & Specialized Solutions |
|
|
523 |
|
|
|
|
518 |
|
|
|
|
5 |
|
|
|
|
486 |
|
|
|
|
37 |
|
Advanced Performance Materials |
|
|
387 |
|
|
|
|
401 |
|
|
|
|
(14 |
) |
|
|
|
388 |
|
|
|
|
(1 |
) |
Other Segment |
|
|
26 |
|
|
|
|
28 |
|
|
|
|
(2 |
) |
|
|
|
30 |
|
|
|
|
(4 |
) |
Total Net Sales |
$ |
|
1,643 |
|
|
$ |
|
1,915 |
|
|
$ |
|
(272 |
) |
|
$ |
|
1,536 |
|
|
$ |
|
107 |
|
Segment Adjusted EBITDA |
|
|
|
|
|
|
|
|
|
Three Months |
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Ended |
|
|
Sequential |
|
|||||||
|
Three Months Ended June 30, |
|
|
Increase / |
|
|
March 31, |
|
|
Increase / |
|
|||||||||||||
|
2023 |
|
|
2022 |
|
|
(Decrease) |
|
|
2023 |
|
|
(Decrease) |
|
||||||||||
Titanium Technologies |
$ |
|
87 |
|
|
$ |
|
216 |
|
|
$ |
|
(129 |
) |
|
$ |
|
70 |
|
|
$ |
|
17 |
|
Thermal & Specialized Solutions |
|
|
214 |
|
|
|
|
213 |
|
|
|
|
1 |
|
|
|
|
185 |
|
|
|
|
29 |
|
Advanced Performance Materials |
|
|
81 |
|
|
|
|
107 |
|
|
|
|
(26 |
) |
|
|
|
84 |
|
|
|
|
(3 |
) |
Other Segment |
|
|
5 |
|
|
|
|
(2 |
) |
|
|
|
7 |
|
|
|
|
10 |
|
|
|
|
(5 |
) |
Corporate and Other |
|
|
(63 |
) |
|
|
|
(59 |
) |
|
|
|
(4 |
) |
|
|
|
(45 |
) |
|
|
|
(18 |
) |
Total Adjusted EBITDA |
$ |
|
324 |
|
|
$ |
|
475 |
|
|
$ |
|
(151 |
) |
|
$ |
|
304 |
|
|
$ |
|
20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Adjusted EBITDA Margin |
|
20 |
% |
|
|
|
25 |
% |
|
|
|
|
|
|
|
20 |
% |
|
|
|
|
|||
Quarterly Change in Net Sales from the three months ended June 30, 2022 |
|
|||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
June 30, 2023 |
|
|
Percentage Change vs. |
|
Percentage Change Due To |
|
|||||||||||||
|
Net Sales |
|
|
June 30, 2022 |
|
Price |
|
Volume |
|
Currency |
|
Portfolio |
|
|||||||
Total Company |
$ |
|
1,643 |
|
|
|
(14 |
)% |
|
2 |
% |
|
(16 |
)% |
|
— |
% |
|
— |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Titanium Technologies |
$ |
|
707 |
|
|
|
(27 |
)% |
|
— |
% |
|
(27 |
)% |
|
— |
% |
|
— |
% |
Thermal & Specialized Solutions |
|
|
523 |
|
|
|
1 |
% |
|
2 |
% |
|
(1 |
)% |
|
— |
% |
|
— |
% |
Advanced Performance Materials |
|
|
387 |
|
|
|
(3 |
)% |
|
7 |
% |
|
(9 |
)% |
|
(1 |
)% |
|
— |
% |
Other Segment |
|
|
26 |
|
|
|
(7 |
)% |
|
19 |
% |
|
(26 |
)% |
|
— |
% |
|
— |
% |
Quarterly Change in Net Sales from the three months ended March 31, 2023 |
|
|||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
June 30, 2023 |
|
|
Percentage Change vs. |
|
Percentage Change Due To |
|
|||||||||||||
|
Net Sales |
|
|
March 31, 2023 |
|
Price |
|
Volume |
|
Currency |
|
Portfolio |
|
|||||||
Total Company |
$ |
|
1,643 |
|
|
|
7 |
% |
|
(1 |
)% |
|
8 |
% |
|
— |
% |
|
— |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Titanium Technologies |
$ |
|
707 |
|
|
|
12 |
% |
|
(1 |
)% |
|
13 |
% |
|
— |
% |
|
— |
% |
Thermal & Specialized Solutions |
|
|
523 |
|
|
|
8 |
% |
|
(1 |
)% |
|
9 |
% |
|
— |
% |
|
— |
% |
Advanced Performance Materials |
|
|
387 |
|
|
|
— |
% |
|
(1 |
)% |
|
1 |
% |
|
— |
% |
|
— |
% |
Other Segment |
|
|
26 |
|
|
|
(13 |
)% |
|
— |
% |
|
(13) |
% |
|
— |
% |
|
— |
% |
The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions)
GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation
Adjusted earnings before interest, taxes, depreciation, and amortization (“Adjusted EBITDA”) is defined as income (loss) before income taxes, excluding the following items: interest expense, depreciation, and amortization; non-operating pension and other post-retirement employee benefit costs, which represents the components of net periodic pension costs excluding the service cost component; exchange (gains) losses included in other income (expense), net; restructuring, asset-related, and other charges; (gains) losses on sales of businesses or assets; and, other items not considered indicative of the Company’s ongoing operational performance and expected to occur infrequently, including Qualified Spend reimbursable by DuPont and/or Corteva as part of the Company's cost-sharing agreement under the terms of the MOU that were previously excluded from Adjusted EBITDA. Adjusted Net Income is defined as net income (loss) attributable to Chemours, adjusted for items excluded from Adjusted EBITDA, except interest expense, depreciation, amortization, and certain provision for (benefit from) income tax amounts.
|
|
Three Months Ended |
|
|
Six Months Ended |
|
|||||||||||||||||||
|
|
June 30, |
|
|
March 31, |
|
|
June 30, |
|
||||||||||||||||
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2023 |
|
|
2022 |
|
||||||||||
Net (loss) income attributable to Chemours |
|
$ |
|
(376 |
) |
|
$ |
|
201 |
|
|
$ |
|
145 |
|
|
$ |
|
(231 |
) |
|
$ |
|
434 |
|
Non-operating pension and other post-retirement employee benefit income |
|
|
|
— |
|
|
|
|
(2 |
) |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
(3 |
) |
Exchange losses, net |
|
|
|
5 |
|
|
|
|
3 |
|
|
|
|
7 |
|
|
|
|
12 |
|
|
|
|
3 |
|
Restructuring, asset-related, and other charges (1) |
|
|
|
(1 |
) |
|
|
|
— |
|
|
|
|
16 |
|
|
|
|
15 |
|
|
|
|
16 |
|
Gain on sales of assets and businesses |
|
|
|
— |
|
|
|
|
(26 |
) |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
(27 |
) |
Qualified spend recovery (2) |
|
|
|
(18 |
) |
|
|
|
(13 |
) |
|
|
|
(14 |
) |
|
|
|
(32 |
) |
|
|
|
(27 |
) |
Legal charges (3) |
|
|
|
644 |
|
|
|
|
5 |
|
|
|
|
1 |
|
|
|
|
645 |
|
|
|
|
7 |
|
Environmental charges (4) |
|
|
|
1 |
|
|
|
|
165 |
|
|
|
|
— |
|
|
|
|
1 |
|
|
|
|
171 |
|
Adjustments made to income taxes (5) |
|
|
|
— |
|
|
|
|
(2 |
) |
|
|
|
(4 |
) |
|
|
|
(4 |
) |
|
|
|
(6 |
) |
Benefit from income taxes relating to reconciling items (6) |
|
|
|
(88 |
) |
|
|
|
(29 |
) |
|
|
|
(3 |
) |
|
|
|
(91 |
) |
|
|
|
(28 |
) |
Adjusted Net Income (7) |
|
|
|
167 |
|
|
|
|
302 |
|
|
|
|
148 |
|
|
|
|
315 |
|
|
|
|
540 |
|
Net income attributable to non-controlling interests |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
1 |
|
|
|
|
— |
|
Interest expense, net |
|
|
|
48 |
|
|
|
|
40 |
|
|
|
|
42 |
|
|
|
|
90 |
|
|
|
|
82 |
|
Depreciation and amortization |
|
|
|
78 |
|
|
|
|
72 |
|
|
|
|
79 |
|
|
|
|
157 |
|
|
|
|
146 |
|
All remaining provision for income taxes (7) |
|
|
|
31 |
|
|
|
|
61 |
|
|
|
|
35 |
|
|
|
|
65 |
|
|
|
|
110 |
|
Adjusted EBITDA |
|
$ |
|
324 |
|
|
$ |
|
475 |
|
|
$ |
|
304 |
|
|
$ |
|
628 |
|
|
$ |
|
878 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Adjusted effective tax rate (7) |
|
|
|
16 |
% |
|
|
|
17 |
% |
|
|
|
19 |
% |
|
|
|
17 |
% |
|
|
|
17 |
% |
(1) |
In 2023, restructuring, asset-related, and other charges primarily includes charges related to our decision to abandon implementation of our new ERP software platform. In 2022, includes asset charges and write-offs resulting from the conflict between |
(2) |
Qualified spend recovery represents costs and expenses that were previously excluded from Adjusted EBITDA, reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the MOU which is discussed in further detail in "Note 17 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023. |
(3) |
Legal charges pertains to litigation settlements, PFOA drinking water treatment accruals, and related legal fees. See “Note 17 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 for further details. |
(4) |
Environmental charges pertains to management’s assessment of estimated liabilities associated with certain non-recurring environmental remediation expenses at various sites. See “Note 17 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 for further details. |
(5) |
Includes the removal of certain discrete income tax impacts within our provision for income taxes, such as shortfalls and windfalls on our share-based payments, certain return-to-accrual adjustments, valuation allowance adjustments, unrealized gains and losses on foreign exchange rate changes, and other discrete income tax items. |
(6) |
The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred for each of the reconciling items and represent both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure. |
(7) |
Adjusted effective tax rate is defined as all remaining provision for income taxes divided by pre-tax Adjusted Net Income. |
The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions, except per share amounts)
GAAP Earnings per Share to Adjusted Earnings per Share Reconciliation
Adjusted earnings per share (“Adjusted EPS”) is calculated by dividing Adjusted Net Income by the weighted-average number of common shares outstanding. Diluted Adjusted EPS accounts for the dilutive impact of stock-based compensation awards, which includes unvested restricted shares. Diluted Adjusted EPS considers the impact of potentially-dilutive securities, except in periods in which there is a loss because the inclusion of the potentially-dilutive securities would have an anti-dilutive effect.
|
|
Three Months Ended |
|
Six Months Ended |
|||||||||||
|
|
June 30, |
|
March 31, |
|
June 30, |
|||||||||
|
|
2023 |
|
2022 |
|
2023 |
|
2023 |
|
2022 |
|||||
Numerator: |
|
|
|
|
|
|
|
|
|
|
|||||
Net (loss) income attributable to Chemours (1) |
|
$ |
(376) |
|
$ |
201 |
|
$ |
145 |
|
$ |
(231) |
|
$ |
434 |
Adjusted Net Income |
|
|
167 |
|
|
302 |
|
|
148 |
|
|
315 |
|
|
540 |
Denominator: |
|
|
|
|
|
|
|
|
|
|
|||||
Weighted-average number of common shares outstanding - basic |
|
|
149,095,543 |
|
|
156,224,802 |
|
|
148,997,084 |
|
|
149,046,585 |
|
|
158,051,092 |
Dilutive effect of the Company's employee compensation plans |
|
|
1,517,177 |
|
|
3,442,411 |
|
|
2,182,181 |
|
|
1,849,679 |
|
|
3,562,159 |
Weighted-average number of common shares outstanding - diluted |
|
|
150,612,720 |
|
|
159,667,213 |
|
|
151,179,265 |
|
|
150,896,264 |
|
|
161,613,251 |
|
|
|
|
|
|
|
|
|
|
|
|||||
Basic (loss) earnings per share of common stock (2) |
|
$ |
(2.52) |
|
$ |
1.29 |
|
$ |
0.97 |
|
$ |
(1.55) |
|
$ |
2.75 |
Diluted (loss) earnings per share of common stock (1) (2) |
|
|
(2.52) |
|
|
1.26 |
|
|
0.96 |
|
|
(1.55) |
|
|
2.69 |
Adjusted basic earnings per share of common stock (2) |
|
|
1.11 |
|
|
1.93 |
|
|
0.99 |
|
|
2.11 |
|
|
3.42 |
Adjusted diluted earnings per share of common stock (1) (2) |
|
|
1.10 |
|
|
1.89 |
|
|
0.98 |
|
|
2.08 |
|
|
3.34 |
(1) |
In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under |
(2) |
Figures may not recalculate exactly due to rounding. Basic and diluted earnings per share are calculated based on unrounded numbers. |
The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(In millions, except per share amounts)
2023 Estimated GAAP Net Loss Attributable to Chemours to Estimated Adjusted Net Income, Estimated Adjusted EBITDA and Estimated Adjusted EPS Reconciliation (*)
|
|
(Estimated) |
|
|||||
|
|
Year Ending December 31, 2023 |
|
|||||
|
|
Low |
|
|
High |
|
||
Net loss attributable to Chemours |
|
$ |
(97 |
) |
|
$ |
(47 |
) |
Restructuring, transaction, and other costs, net (1) |
|
|
592 |
|
|
|
592 |
|
Adjusted Net Income |
|
|
495 |
|
|
|
545 |
|
Interest expense, net |
|
|
200 |
|
|
|
200 |
|
Depreciation and amortization |
|
|
300 |
|
|
|
300 |
|
All remaining provision for income taxes |
|
|
105 |
|
|
|
130 |
|
Adjusted EBITDA |
|
$ |
1,100 |
|
|
$ |
1,175 |
|
|
|
|
|
|
|
|
||
Weighted-average number of common shares outstanding - basic (2) |
|
|
148.6 |
|
|
|
148.6 |
|
Dilutive effect of the Company's employee compensation plans (3) |
|
|
2.9 |
|
|
|
2.9 |
|
Weighted-average number of common shares outstanding – diluted |
|
|
151.5 |
|
|
|
151.5 |
|
|
|
|
|
|
|
|
||
Basic loss per share of common stock |
|
$ |
(0.65 |
) |
|
$ |
(0.32 |
) |
Diluted loss per share of common stock (4) |
|
|
(0.65 |
) |
|
|
(0.32 |
) |
Adjusted basic earnings per share of common stock |
|
|
3.33 |
|
|
|
3.67 |
|
Adjusted diluted earnings per share of common stock (4) |
|
|
3.27 |
|
|
|
3.60 |
|
(1) |
Restructuring, transaction, and other costs, net includes the net provision for (benefit from) income taxes relating to reconciling items and adjustments made to income taxes for the removal of certain discrete income tax impacts; qualified spend recovery; gain associated with the sale of our Glycolic Acid business; and costs related to legal settlements for legacy environmental matters and associated fees (including the recent PFAS settlement with |
(2) |
The Company’s estimates for the weighted-average number of common shares outstanding - basic reflect results for the six months ended June 30, 2023, which are carried forward for the projection period. |
(3) |
The Company’s estimates for the dilutive effect of the Company’s employee compensation plans reflect the dilutive effect for the six months ended June 30, 2023, which is carried forward for the projection period. |
(4) |
Diluted earnings per share is calculated using net income available to common shareholders divided by diluted weighted-average common shares outstanding during each period, which includes unvested restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect. |
(*) The Company’s estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these current estimates |
|
The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions)
GAAP Cash Flow Provided by (Used for) Operating Activities to Free Cash Flows Reconciliation
Free Cash Flows is defined as cash flows provided by (used for) operating activities, less purchases of property, plant, and equipment as shown in the consolidated statements of cash flows.
|
|
Three Months Ended |
|
|
Six Months Ended |
|
|||||||||||||||||||
|
|
June 30, |
|
|
March 31, |
|
|
June 30, |
|
||||||||||||||||
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2023 |
|
|
2022 |
|
||||||||||
Cash provided by (used for) operating activities |
|
$ |
|
61 |
|
|
$ |
|
291 |
|
|
$ |
|
(119 |
) |
|
$ |
|
(58 |
) |
|
$ |
|
293 |
|
Less: Purchases of property, plant, and equipment |
|
|
|
(58 |
) |
|
|
|
(62 |
) |
|
|
|
(91 |
) |
|
|
|
(149 |
) |
|
|
|
(168 |
) |
Free Cash Flows |
|
$ |
|
3 |
|
|
$ |
|
229 |
|
|
$ |
|
(210 |
) |
|
$ |
|
(207 |
) |
|
$ |
|
125 |
|
2023 Estimated GAAP Cash Flow Provided by Operating Activities to Estimated Free Cash Flow Reconciliation (*)
|
|
(Estimated) |
|
|
|
Year Ending December 31, 2023 |
|
Cash flow provided by operating activities |
|
$ |
>725 |
Less: Purchases of property, plant, and equipment |
|
|
~(400) |
Free Cash Flows |
|
$ |
>325 |
(*) Assumes future cash payments of approximately |
|
The Company’s estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these current estimates. |
Return on Invested Capital Reconciliation
Return on Invested Capital (“ROIC”) is defined as Adjusted EBITDA, less depreciation and amortization (“Adjusted EBIT”), divided by the average of invested capital, which amounts to net debt, or debt less cash and cash equivalents, plus equity.
|
|
Twelve Months Ended June 30, |
|
|||||
|
|
2023 |
|
|
2022 |
|
||
Adjusted EBITDA (1) |
|
$ |
1,111 |
|
|
$ |
1,557 |
|
Less: Depreciation and amortization |
|
|
(303 |
) |
|
|
(300 |
) |
Adjusted EBIT |
|
$ |
808 |
|
|
$ |
1,257 |
|
|
|
|
|
|
|
|
||
|
|
As of June 30, |
|
|||||
|
|
2023 |
|
|
2022 |
|
||
Total debt, net (2) |
|
$ |
3,629 |
|
|
$ |
3,680 |
|
Total equity |
|
|
810 |
|
|
|
1,215 |
|
Less: Cash and cash equivalents |
|
|
(738 |
) |
|
|
(1,248 |
) |
Invested capital, net |
|
$ |
3,701 |
|
|
$ |
3,647 |
|
Average invested capital (3) |
|
$ |
3,731 |
|
|
$ |
3,667 |
|
|
|
|
|
|
|
|
||
Return on Invested Capital |
|
|
22 |
% |
|
|
34 |
% |
- Reconciliations of net (loss) income attributable to Chemours to Adjusted EBITDA are provided on a quarterly basis. See the preceding table for the reconciliation of net (loss) income attributable to Chemours to Adjusted EBITDA.
-
Total debt principal minus unamortized issue discounts of
$4 $5 million $20 $25 million -
Average invested capital is based on a five-quarter trailing average of invested capital, net.
The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions)
Net Leverage Ratio Reconciliation
Net Leverage Ratio is defined as our total debt principal, net, or our total debt principal outstanding less cash and cash equivalents, divided by Adjusted EBITDA.
|
|
As of June 30, |
|
|||||
|
|
2023 |
|
|
2022 |
|
||
Total debt principal |
|
$ |
3,653 |
|
|
$ |
3,710 |
|
Less: Cash and cash equivalents |
|
|
(738 |
) |
|
|
(1,248 |
) |
Total debt principal, net |
|
$ |
2,915 |
|
|
$ |
2,462 |
|
|
|
|
|
|
|
|
||
|
|
Twelve Months Ended June 30, |
|
|||||
|
|
2023 |
|
|
2022 |
|
||
Adjusted EBITDA (1) |
|
$ |
1,111 |
|
|
$ |
1,557 |
|
|
|
|
|
|
|
|
||
Net Leverage Ratio |
|
2.6x |
|
|
1.6x |
|
||
(1) |
Reconciliations of net (loss) income attributable to Chemours to Adjusted EBITDA are provided on a quarterly basis. See the preceding table for the reconciliation of net (loss) income attributable to Chemours to Adjusted EBITDA. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20230727296846/en/
INVESTORS
Brandon Ontjes
VP, FP&A and Investor Relations
+1.302.773.3309
investor@chemours.com
Kurt Bonner
Manager, Investor Relations
+1.302.773.0026
investor@chemours.com
NEWS MEDIA
Thom Sueta
Director, Corporate Communications
+1.302.773.3903
media@chemours.com
Source: The Chemours Company
FAQ
What were Chemours' second quarter net sales and adjusted EBITDA?
What is the reason for the closure of Chemours' Kuan Yin facility?
What is the impact of the closure of the Kuan Yin facility?
What is the updated full-year adjusted EBITDA guidance?
